CHARLOTTESVILLE, Va., Jan. 22, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human-relevant systems for drug development and discovery, today announced that it will expand and relocate its operations to downtown Charlottesville, Virginia. The Company will initially lease 14,800 square feet of the Cardwell Building in the historic former Martha Jefferson Hospital, now owned by Octagon Partners. The lease allows for expansion to additional floors, as HemoShear's business requires.
HemoShear has grown to more than 30 employees since launching operations in 2009. The Company continues to expand its customer base, which includes most major biopharmaceutical companies, by deploying its human-relevant systems and scientific expertise to reduce new drug R&D costs and improve success rates of new drug candidates. In 2012, HemoShear received the Rocket Award from the Charlottesville Business Innovation Council for rapid commercialization of a new technology.
The renovated Cardwell space will allow for continued growth as HemoShear increases the scope of its pharmaceutical customer partnerships and its technology development. Nicole Hastings, Ph.D., Vice President of Operations, said, "The Cardwell Building has an ideal infrastructure. The new space allows us to design for improved workflow, optimal productivity and quality. We are also excited to be located near all of the downtown Charlottesville activities and to contribute to the growth of the Charlottesville bioscience community."
Demolition for the new space is underway and HemoShear is actively planning for its move to the Cardwell Building in mid-2013. Mark Mascotte of MFM Partners, LLC, represented the landlord in the lease transaction. StellarOne Bank and the Commonwealth of Virginia provided financial assistance to HemoShear. Local contractor Vision Building & Design, LLC will perform the demolition, design and space outfit.
About HemoShear LLC
HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.
SOURCE HemoShear LLC